Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age
Sponsor: GlaxoSmithKline
Listed as NCT00307541, this PHASE3 trial focuses on Infections, Streptococcal and Streptococcus Pneumoniae Vaccines and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Lobenstein, Germany , Bad Oeynhausen, Germany , Berlin, Germany , Erkrath, Germany , Frankenthal, Germany , Gerolstein, Germany , Goch, Germany , Heiligenhaus, Germany , Leipzig, Germany , Mainz, Germany and 16 more locations